Roxadustat, marketed under the brand name Evrenzo, is a revolutionary anti-anemia medication notably used for the treatment of anemia associated with chronic kidney disease (CKD). This innovative drug works by inhibiting hypoxia-inducible factor prolyl-hydroxylase (HIF-PH), leading to an increase in endogenous production of erythropoietin, a hormone essential for the production of red blood cells. By inducing erythropoiesis, Roxadustat stimulates the production of hemoglobin and red blood cells, thereby ameliorating symptoms associated with anemia.
Parent: Roxadustat
Roxadustat, like all drugs, has an inevitably associated impurity profile. During its manufacturing process, certain impurities may arise, such as process-related impurities (residual solvents, reagents, or raw materials), and degradation products that come about due to the drug’s instability. In the essence of pharmaceutical safety and efficacy, the impurity level in Roxadustat is minutely controlled and limited to trace amounts, typically in microgram or nanogram quantities. It is always of paramount importance that these impurities are thoroughly characterized, identified, and quantified, ensuring patient safety.
Roxadustat is primarily used to treat anemia associated with chronic kidney disease (CKD). Anemia is a common complication in patients with CKD. Roxadustat enhances the natural process of erythropoiesis, i.e., red blood cell production, thereby alleviating anemia symptoms in these patients.
The FDA issued a Complete Response Letter (CRL) for roxadustat for the treatment of anemia of CKD. The FDA cited the need for additional clarification and analyses of clinical data already submitted, but did not demand any new clinical trials, thus asserting the possibility of its future approval.
Roxadustat, as a hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitor, can increase the production of red blood cells in the body. This can potentially enhance the oxygen-carrying capacity of the blood, in turn enhancing performance. Thus, it falls under the category of substances prohibited in sports due to their potential misuse for doping.
Roxadustat works by inhibiting the enzyme hypoxia-inducible factor prolyl-hydroxylase (HIF-PH), which normally limits the production of erythropoietin (EPO). With HIF-PH inhibited, there is increased production of EPO, which in turn stimulates the production of red blood cells and hemoglobin. This helps alleviate the symptoms of anemia.
